Separation of new antidepressants and their metabolites by micellar electrokinetic capillary chromatography

All-Solid State Potentiometric Sensors for Desvenlafaxine Detection Using Biomimetic Imprinted Polymers as Recognition Receptors

Using single-walled carbon nanotubes (SWCNTs) as an ion-to-electron transducer, a novel disposable all-solid-state desvenlafaxine-selective electrode based on a screen-printed carbon paste electrode was created. SWCNTs were put onto the carbon-paste electrode area, which was protected by a poly (vinyl chloride) (PVC) membrane with a desvenlafaxine-imprinted polymer serving as a recognition receptor. Electrochemical impedance spectroscopy and chronopotentiometric techniques were used to examine the electrochemical characteristics of the SWCNTs/PVC coating on the carbon screen-printed electrode. The electrode displayed a 57.2 ± 0.8 mV/decade near-Nernstian slope with a 2.0 × 10^-6 M detection limit. In 10 mM phosphate buffer, pH 6, the ODV-selective electrodes displayed a quick reaction (5 s) and outstanding stability, repeatability, and reproducibility. The usefulness of electrodes was demonstrated in samples of ODV-containing pharmaceutical products and human urine. These electrodes have the potential to be mass produced and employed as disposable sensors for on-site testing, since they are quick, practical, and inexpensive.

Molecularly Imprinted Polymer Nanoparticles for Selective Solid Phase Extraction of Fluvoxamine in Human Urine and Plasma

In this work, the molecularly imprinted polymer nanoparticles (MIP-NPs) for the selective determination of fluvoxamine have been described. The polymer nanoparticles were synthesized by the polymerization of methacrylic acid as a functional monomer, ethylene glycol dimethacrylate as a cross-linker, 2,2-azobisisobutyronitrile as an initiator and fluvoxamine as a template molecule. The MIP-NPs were characterized using techniques that included Fourier transform infrared (FT-IR) spectroscopy and scanning electron microscopy (SEM). Imprinted fluvoxamine molecules were removed from the polymeric structure using acetonitrile in methanol (2:8; v/v) as the eluting solvent. The linear dynamic range for fluvoxamine was 10-1200 μg L-1. The developed method was successfully applied to the extraction of fluvoxamine in complex biological samples.

Simultaneous Quantification of Citalopram and its Main Metabolite, Desmethylcitalopram, in Human Saliva by UHPLC

Background:

This study was designed to develop a reliable method for simultaneous quantita-tion of Citalopram (CIT) and its main active metabolite, Desmethylcitalopram (DCIT), in saliva of patients undergoing treatment with CIT.

Methods:

To compare two procedures of saliva purification, Solid-Phase (SPE) and Liquid-Liquid (LLE) extractions, saliva samples obtained from healthy volunteers were spiked with adequate quantities of CIT and DCIT. Different cartridges were used for SPE, while dichloromethane for LLE. Chromatographic separation and quantitation were carried out by UHPLC with DAD detector using a C-18 column and a mixture of acetonitrile and redistilled water (37:63, v:v) with the addition of formic acid (pH 3.5) as a mobile phase.

Results:

A comparison of both purification procedures showed that the most satisfactory results were obtained by SPE using Discovery C18 cartridge and redistilled water with formic acid (pH 3.5) as a washing solvent. Dichloromethane proved to be the best extractant in LLE. Both procedures enabled the separation of analytes from human saliva with high precision and recovery.

Conclusions:

Validation of the developed UHPLC procedure revealed that, regardless of how the sample was purified, the method was characterized by good linearity (between 10 and 1000 ng/mL), sensitivity, reproducibility, specificity and low values of limits of detection and quantitation. The limits of quantitation were 4.0 and 8.0 ng/mL for SPE and LLE, respectively. The efficiency of the method in therapeutic drug monitoring of CIT and DCIT in saliva of patients was confirmed.

Dispersive liquid-liquid microextraction for the quantification of venlafaxine in environmental waters

The present work describes a new methodology for the detection of the antidepressant venlafaxine (VEN) in aquatic environments using dispersive liquid-liquid microextraction followed by high performance liquid chromatography with fluorescence detection (DLLME-HPLC-FLD). The method developed is fast, low cost, easy to apply, uses a small volume of organic solvents and allows the simultaneous extraction of various samples. The DLLME-HPLC-FLD method presented a linearity range from 25 to 1500 ng L^-1, a detection limit of 24.2 ± 0.2 ng L^-1, and an enrichment factor of 75 ± 4. Recovery tests using solutions of NaCl and humic acids showed that ionic strength and organic matter do not influence the efficiency of the extraction, with extraction recoveries above 77%. Finally, the optimized method was applied to the analysis of water samples from different origins and VEN was only detected in one water sample obtained from a waste water treatment plant (WWTP), which had a concentration of 175 ± 5 ng L^-1. Recovery tests performed in environmental aquatic samples demonstrated that the developed extraction procedure is not influenced by the complex water matrices, with results ranging from 76 to 93%.

Determination of antidepressants in human urine extracted by magnetic multiwalled carbon nanotube poly(styrene-co-divinylbenzene) composites and separation by capillary electrophoresis

Poly(styrene-co-divinylbenzene)-coated magnetic multiwalled carbon nanotube composite synthesized by in-situ high temperature combination and precipitation polymerization of styrene-co-divinylbenzene has been employed as a magnetic sorbent for the solid phase extraction of antidepressants in human urine samples. Fluoxetine, venlafaxine, citalopram and sertraline were, afterwards, separated and determined by capillary electrophoresis with diode array detection. The presence of magnetic multiwalled carbon nanotubes in native poly(styrene-co-divinylbenzene) not only simplified sample treatment but also enhanced the adsorption efficiencies, obtaining extraction recoveries higher than 89.5% for all analytes. Moreover, this composite can be re-used at least ten times without loss of efficiency and limits of detection ranging from 0.014 to 0.041 μg/mL were calculated. Additionally, precision values ranging from 0.08 to 7.50% and from 0.21 to 3.05% were obtained for the responses and for the migration times of the analytes, respectively.

Bioanalytical method development and validation of milnacipran in rat plasma by LC-MS/MS detection and its application to a pharmacokinetic study

A simple, sensitive and specific liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the quantification of milnacipran (MC) in rat plasma by using the liquid–liquid extraction method. Milnacipran-d10 (MCD10) was used as an internal standard (IS). Chromatographic separation was achieved on Zorbax SB-CN (4.6 mm×75 mm, 3.5 µm) column with an isocratic mobile phase composed of 10 mM ammonium acetate (pH 4.0) and methanol in the ratio of 25:75(v/v), at a flow-rate of 0.7 mL/min. MC and MCD10 were detected with proton adducts at m/z 247.2→230.3 and m/z 257.2→240.4 in multiple reaction monitoring (MRM) positive mode respectively. The method was validated over a linear concentration range of 1.00–400.00 ng/mL with a correlation coefficient (r²)≥0.9850. This method demonstrated intra- and inter-day precision within 5.40–10.85% and 4.40–8.29% and accuracy within 97.00–104.20% and 101.64–106.23%. MC was found to be stable throughout three freeze–thaw cycles, bench top and postoperative stability studies. This method was successfully applied to a pharmacokinetic study of rats through i.v. administration.

Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples

Spectrofluorometric analysis for the quantification of new-generation antidepressant drugs belong to the class of selective serotonin reuptake inhibitors and selective norepinephrine reuptake inhibitors is described. Five different drugs, sertraline, paroxetine, citalopram, venlafaxine, and fluoxetine, were analysed for spectrofluorometric detection in pharmaceutical formulations and urine and plasma samples. The calibration curves were found linear between fluorescence intensity and drugs concentration in the range of 5–500 ng/L with coefficients of determination above 0.9985 for all the analytes. The method recoveries were higher than 85% in all the three matrices. The intra- and interday variation coefficients were observed less than 8% and 13%, respectively. The limits of detection (LOD) and limit of quantification (LOQ) were found in the range of 0.016–0.084 ng/L and 0.090–0.285 ng/L, respectively. Additionally, the results were compared statistically for each analyte in all the three matrices and were found equivalent, which signifies the absence of matrix effect. Thus, the method will be applied successfully to the determination of the cited drugs in pure or dosage forms as well as in biological fluids with good accuracy and precision.

Simple spectrophotometric method for determination of paroxetine in tablets using 1,2-naphthoquinone-4-sulphonate as a chromogenic reagent

Simple and rapid spectrophotometric method has been developed and validated for the determination of paroxetine (PRX) in tablets. The proposed method was based on nucleophilic substitution reaction of PRX with 1,2-naphthoquinone-4-sulphonate (NQS) in an alkaline medium to form an orange-colored product of maximum absorption peak (λ_max) at 488 nm. The stoichiometry and kinetics of the reaction were studied, and the reaction mechanism was postulated. Under the optimized reaction conditions, Beer's law correlating the absorbance (A) with PRX concentration (C) was obeyed in the range of 1–8 μg mL⁻¹. The regression equation for the calibration data was: A = 0.0031 + 0.1609 C, with good correlation coefficients (0.9992). The molar absorptivity (ε) was 5.9 × 10⁵ L mol⁻¹ 1 cm⁻¹. The limits of detection and quantitation were 0.3 and 0.8 μg mL⁻¹, respectively. The precision of the method was satisfactory; the values of relative standard deviations did not exceed 2%. The proposed method was successfully applied to the determination of PRX in its pharmaceutical tablets with good accuracy and precisions; the label claim percentage was 97.17 ± 1.06 %. The results obtained by the proposed method were comparable with those obtained by the official method.

New spectrofluorimetric method with enhanced sensitivity for determination of paroxetine in dosage forms and plasma

New simple spectrofluorimetric method with enhanced sensitivity has been developed and validated for the determination of the antidepressant paroxetine (PXT) in its dosage forms and plasma. The method was based on nucleophilic substitution reaction of PXT with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole in an alkaline medium (pH 8) to form a highly fluorescent derivative that was measured at 545 nm after excitation at 490 nm. The factors affecting the reaction was carefully studied and optimized. The kinetics of the reaction was investigated, and the reaction mechanism was presented. Under the optimized conditions, linear relationship with good correlation coefficient (0.9993) was found between the fluorescence intensity and PXT concentration in the range of 80-800 ng ml(-1). The limits of detection and quantitation for the method were 25 and 77 ng ml(-1), respectively. The precision of the method was satisfactory; the values of relative standard deviations did not exceed 3%. The proposed method was successfully applied to the determination of PXT in its pharmaceutical tablets with good accuracy; the recovery values were 100.2 +/- 1.61%. The results obtained by the proposed method were comparable with those obtained by the official method. The proposed method is superior to the previously reported spectrofluorimetric method for determination of PXT in terms of its higher sensitivity and wider linear range. The high sensitivity of the method allowed its successful application to the analysis of PXT in spiked human plasma. The proposed method is practical and valuable for its routine application in quality control and clinical laboratories for analysis of PXT.

Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma

A gas chromatographic-mass spectrometric method (GC-MS) for the simultaneous determination of the 'new' antidepressants (mirtazapine, viloxazine, venlafaxine, trazodone, citalopram, mianserin, reboxetine, fluoxetine, fluvoxamine, sertraline, maprotiline, melitracen, paroxetine) and their active metabolites (desmethylmirtazapine, O-desmethylvenlafaxine, m-chlorophenylpiperazine, desmethylcitalopram, didesmethylcitalopram, desmethylmianserin, desmethylfluoxetine, desmethylsertraline, desmethylmaprotiline) in plasma using different ionization modes was developed and validated. Sample preparation consisted of a strong cation exchange mechanism and derivatisation with heptafluorobutyrylimidazole. The GC separation was performed in 24.8 min. Identification and quantification were based on selected ion monitoring in electron (EI) and chemical ionization (CI) modes. Calibration by linear and quadratic regression for electron and chemical ionization, respectively, utilized deuterated internal standards and a weighing factor 1/x(2). Limits of quantitation were established between 5 and 12.5 ng/ml in EI and positive ionization CI (PICI), and 1 and 6.25 ng/ml in negative ionization CI (NICI). During validation stability, sensitivity, precision, accuracy, recovery, and selectivity were evaluated for each ionization mode and were demonstrated to be acceptable for most compounds. While it is clear that not all compounds can be quantitated either due to chromatographic (trazodone) or derivatisation problems (O-desmethylvenlafaxine), this method can quantitate most new antidepressants (ADs) in the therapeutic range using EI. PICI and NICI lead to higher selectivity. Moreover, NICI is of interest for small sample volumes and high sensitivity requirements. This paper draws the attention to the pros and cons of the different ionization modes in the GC-MS analysis of these antidepressants in plasma.

Determination of sertraline andN-desmethylsertraline in human plasma by CE with LIF detection

A method has been developed for the analysis of the antidepressant drug sertraline together with its main metabolite N-desmethylsertraline (DMS) in human plasma. It is based on CE with LIF detection (lambda = 488 nm). A SPE procedure is employed for biological sample pretreatment, followed by a derivatization step with FITC; reboxetine was the internal standard. The effect of CD, acetone and N-methyl-D-glucamine (GLC) as constituents of the BGE for analyte separation was investigated. The final BGE consisted of 20 mM carbonate buffer, pH 9.0, with 2.5 mM heptakis(2,6-di-O-methyl)-beta-CD, 50 mM GLC and 20% v/v acetone. With 30 kV applied voltage, the electrophoretic run is completed in 7.5 min. Linearity was observed in the plasma concentration range from 3.0 to 500 ng/mL for sertraline and 4.0 to 500 ng/mL for DMS. Extraction yield was >97.1%, precision - expressed as RSD% - was <3.7, accuracy (recovery) was >95.6%. Due to its sensitivity and selectivity, the method was suited for the analysis of plasma samples from patients undergoing therapy with sertraline.

HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies

A simple, specific and sensitive high-performance liquid chromatographic (HPLC) method has been developed for the assay of fluvoxamine in human plasma and urine. The method was based on reaction of fluvoxamine with 1,2-naphthoquinone-4-sulphonic acid sodium salt (NQS) forming orange colored product. The fluvoxamine-NQ derivative was separated by isocratic reversed-phase HPLC and detected at 450 nm. The chromatographic conditions were as follows: Phenomenex C(18) (250 mm x 4.6 mm i.d., 5 microm) column, mobile phase consisting of acetonitrile/water (80:20 v/v) at a flow rate of 1 ml/min. Tryptamine was selected as an internal standard. The assay was linear over the concentration range of 5-145 and 2-100 ng/ml for plasma and urine, respectively. The limits of detection (LOD) were 1.4 and 1 ng/ml for plasma and urine estimation at a signal-to-noise (S/N) ratio of 3. The limits of quantification (LOQ) were 5 and 2 ng/ml for plasma and urine, respectively. The extraction recoveries were found to be 96.66+/-0.69 and 96.73+/-2.17% for plasma and urine, respectively. The intra-day and inter-day standard deviations (S.D.) were less than 1. The method indicated good performance in terms of specificity, linearity, detection and quantification limits, precision and accuracy. This assay was demonstrated to be applicable for clinical pharmacokinetic studies.

Solid-phase microextraction–liquid chromatography (SPME–LC) determination of fluoxetine and norfluoxetine in plasma using a heated liquid flow through interface

A simple and sensitive procedure using solid-phase microextraction coupled with high performance liquid chromatography (HPLC) to analyze fluoxetine (FLU) and its metabolite norfluoxetine (nor-FLU) in plasma samples was developed and validated. SPME conditions were optimized employing a factorial design. The sampling step was performed using a PDMS-DVB fiber and desorption was carried out in a novel homemade heated interface. Fluoxetine and norfluoxetine were analyzed by HPLC, using a C18 Phase Sep column (150mmx4.6mm, 3microm) packed "in house", and acetonitrile:acetate buffer 25mmoll(-1) with triethylamine 25mmoll(-1) pH 4.6 (70:30) as the mobile phase. The developed method has shown precision, linearity, specificity, and limit of quantification (LOQ) adequate to assay fluoxetine and norfluoxetine in plasma. Furthermore, the results obtained using the homemade interface has shown an improvement in the desorption process when compared with the results obtained using the off-line mode.

Characterization of the trace-level impurities in the bulk drug citalopram by high-performance liquid chromatography/tandem multistage mass spectrometry

Five trace impurities were detected in the bulk drug citalopram using high-performance liquid chromatography with UV detection. A simple and sensitive method suitable for liquid chromatography tandem multistage mass spectrometry (HPLC/MS(n)) analysis was developed. Using this method, the fragmentation behavior of citalopram and the impurities was investigated. Four impurities were rapidly characterized, and an unknown impurity was elucidated as 3-(3-dimethylaminopropyl)-N-(1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)-3-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide on the basis of the MS(n) and exact mass evidence, and the proposed structure was further confirmed by nuclear magnetic resonance (NMR) experiments after preparative isolation.

Electroanalytical determination of paroxetine in pharmaceuticals

Electroanalytical methods based on square-wave adsorptive-stripping voltammetry (SWAdSV) and flow-injection analysis with SWAdSV detection (FIA-SWAdSV) were developed for the determination of paroxetine (PRX). The methods were based on the reduction of PRX at a mercury drop electrode at -1.55V versus Ag/AgCl, in a borate buffer of pH 8.8, and the possibility of accumulating the compound at the electrode surface. Because the presence of dissolved oxygen did not interfere significantly with the analysis, it was also possible to determine PRX using FIA-SWAdSV. This method enables analysis of up to 120 samples per hour at reduced costs. Both methods developed were validated and successfully applied to the quantification of PRX in pharmaceutical products.